Atrial Fibrillation Also called: AF, Afib

Clinical Trial Finder

Many patients with atrial fibrillation are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Atrial Tachycardia as a Predictor of Atrial Fibrillation, Stroke and Mortality in Cryptogenic Stroke

Conditions:   Cryptogenic Stroke;   Atrial Fibrillation;   Atrial Tachycardia
Intervention:   Other: follow-up
Sponsor:   Corporacion Parc Tauli
Active, not recruiting - verified February 2015

Left Atrial Geometry and Outcomes After Atrial Fibrillation Ablation

Conditions:   Atrial Fibrillation;   Recurrence
Intervention:  
Sponsors:   Hospital Clinic of Barcelona;   Germans Trias i Pujol Hospital;   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau;   Hospital del Mar;   Hospital Virgen de la Salud;   Hospital San Carlos, Madrid;   Fundación para la Investigación del Hospital Clínico de Valencia;   Complexo Hospitalario Universitario de Vigo;   Puerta de Hierro University Hospital
Active, not recruiting - verified February 2015

Validation of Ambulatory Sleep Test (WP200/U) Compared In-lab Sleep Testing in Cardiac Subjects

Condition:   Sleep Disorders
Intervention:  
Sponsor:   Itamar-Medical, Israel
Not yet recruiting - verified February 2015

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

Condition:   Atrial Fibrillation
Interventions:   Drug: Warfarin;   Drug: Dabigatran Etexilate 150mg
Sponsor:   Boehringer Ingelheim
Not yet recruiting - verified February 2015

TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Post Approval Study

Condition:   Paroxysmal Atrial Fibrillation
Intervention:   Device: TactiCath Quartz treatment
Sponsor:   St. Jude Medical
Recruiting - verified February 2015

Ganglionated Plexus Ablation For Treatment of Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Procedure: Image guided GP ablation;   Device: D-SPECT dedicated cardiac nuclear camera
Sponsor:   Spectrum Dynamics
Recruiting - verified February 2015

The Influence of Preoperative Warfarin Medication on Thromboelastography and Blood Transfusion

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Konkuk University Medical Center
Completed - verified February 2015

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: Dabigatran Etexilate 110mg;   Drug: Warfarin 3mg;   Drug: Aspirin;   Drug: Dabigatran Etexilate 150mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 5mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 1mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2015

Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers

Condition:   Atrial Fibrillation
Interventions:   Drug: BMS-919373;   Drug: Sotalol;   Drug: Placebo for BMS-919373
Sponsor:   Bristol-Myers Squibb
Recruiting - verified January 2015

Early Post-marketing Study of Eliquis (Apixaban)

Condition:   Non-valvular Atrial Fibrillation (NVAF)
Intervention:   Drug: Apixaban
Sponsor:   Bristol-Myers Squibb
Recruiting - verified February 2015

HEart and BRain Interfaces in Acute Ischemic Stroke

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsors:   Charite University, Berlin, Germany;   Center for Stroke Research Berlin;   Neurology, Charite University, Berlin, Germany
Recruiting - verified February 2015

A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

Condition:   Paroxysmal Atrial Fibrillation
Interventions:   Drug: BMS-919373;   Drug: Placebo (Matching with BMS-919373)
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2014

Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque

Condition:   Atrial Fibrillation
Interventions:   Drug: apixaban;   Drug: warfarin
Sponsor:   Los Angeles Biomedical Research Institute
Recruiting - verified February 2015

Botulinum Toxin Injection Prevent Paroxysmal Atrial Fibrillation

Condition:   Paroxysmal Atrial Fibrillation
Intervention:   Procedure: endomyocardial BT injection
Sponsor:   Meshalkin Research Institute of Pathology of Circulation
Recruiting - verified February 2015

Pulmonary Vein Isolation Versus Botulinum Toxin Injection Plus Pulmonary Vein Isolation in Patients With Atrial Fibrillation

Conditions:   Paroxysmal Atrial Fibrillation;   Persistent Atrial Fibrillation
Interventions:   Procedure: Pulmonary vein isolation;   Drug: Botulinum Toxin
Sponsor:   Meshalkin Research Institute of Pathology of Circulation
Recruiting - verified February 2015

Radiofrequency Ablation Plus Botulinum Toxin Injection Versus Radiofrequency Ablation Only in Patients With Atrial Flutter

Condition:   Atrial Flutter
Interventions:   Procedure: radiofrequency ablation;   Drug: Botulinum Toxin Type A injection
Sponsor:   Meshalkin Research Institute of Pathology of Circulation
Recruiting - verified February 2015

Hip Fracture Impact on Vascular Events In Noncardiac Surgery patIents: a cOhort evaluatioN (Hip VISION): Pilot Study

Condition:   Hip Fractures
Intervention:  
Sponsor:   Population Health Research Institute
Active, not recruiting - verified February 2015

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

Conditions:   Atrial Fibrillation;   Atrial Flutter
Interventions:   Drug: bucindolol hydrochloride;   Drug: metoprolol succinate
Sponsors:   ARCA Biopharma, Inc.;   Medtronic
Recruiting - verified February 2015

Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

Condition:   Atrial Fibrillation
Intervention:   Drug: Pradaxa, dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2015

The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

Conditions:   Atrial Fibrillation;   Heart Failure
Interventions:   Drug: Ranolazine;   Drug: Placebo
Sponsors:   Intermountain Health Care, Inc.;   Gilead Sciences
Terminated - verified June 2013

Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)

Condition:   Non-valvular Atrial Fibrillation
Intervention:   Drug: Apixaban
Sponsor:   Bristol-Myers Squibb
Recruiting - verified December 2014

Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism

Condition:   Atrial Fibrillation
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsor:   Bayer
Completed - verified February 2015

nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Device: nMARQ Navigation Catheters;   Device: NaviStar ThermoCool Catheters
Sponsor:   Biosense Webster, Inc.
Recruiting - verified February 2015

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: rivaroxaban 2.5 mg;   Drug: rivaroxaban 15 mg;   Drug: rivaroxaban 10 mg;   Drug: aspirin (ASA);   Drug: vitamin K antagonist (VKA);   Drug: clopidogrel;   Drug: prasugrel;   Drug: ticagrelor
Sponsors:   Janssen Scientific Affairs, LLC;   Bayer
Recruiting - verified February 2015

Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF

Condition:   Atrial Fibrillation
Interventions:   Biological: Canakinumab;   Biological: Placebo
Sponsor:   University Hospital, Basel, Switzerland
Recruiting - verified February 2015

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia

Condition:   Atrial Fibrillation
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsor:   Bayer
Recruiting - verified February 2015

Left Atrial Appendage (LAA) Occluders After Catheter Ablation of Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Device: LAA occluder;   Procedure: RFA ablation;   Drug: Warfarin
Sponsor:   Meshalkin Research Institute of Pathology of Circulation
Recruiting - verified February 2015

Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation

Condition:   Paroxysmal Atrial Fibrillation (PAF)
Interventions:   Device: Blazer Open-Irrigated Ablation Catheter (Boston Scientific);   Device: FDA Approved Open-Irrigated Ablation Catheter
Sponsor:   Boston Scientific Corporation
Recruiting - verified February 2015

A Healthy Volunteer Study to Investigate the Blood Concentrations, the Effect on Blood Clotting and the Safety of Multiple Doses of DPOC-4088 Tablets in Different Doses.

Conditions:   Deep Vein Thrombosis Leg;   Stroke (in Patients With Atrial Fibrillation)
Interventions:   Drug: DPOC-4088;   Drug: Placebo
Sponsors:   Diakron Pharmaceuticals;   Drug Research Unit Ghent, Ghent, Belgium;   Kinesis Pharma BV, Breda, the Netherlands
Terminated - verified July 2012

Cryoablation in Patients With Atrial Flutter

Condition:   Atrial Flutter
Interventions:   Procedure: Cryoballoon ablation;   Procedure: Implantation of loop recorder;   Procedure: Radiofrequency ablation
Sponsor:   Meshalkin Research Institute of Pathology of Circulation
Recruiting - verified February 2015

Deviating the Esophagus in Atrial Fibrillation Ablation

Conditions:   Esophageal Deviation;   Atrial Fibrillation;   Ablation
Intervention:   Device: esophageal deviation with IDE device
Sponsors:   Vivek Reddy;   Boston Scientific Corporation
Terminated - verified February 2015

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Conditions:   Atrial Fibrillation;   Paroxysmal Atrial Fibrillation;   Persistent Atrial Fibrillation
Interventions:   Drug: OPC-108459;   Drug: Placebo
Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified February 2015

Rate Ventricular Control Therapy in Patients With Permanent Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Device: implantable continuous monitor
Sponsor:   Meshalkin Research Institute of Pathology of Circulation
Recruiting - verified February 2015

Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia

Conditions:   AtrioVentricular Nodal Reentrant Tachycardia;   Supraventricular Tachycardia;   Heart Disease
Intervention:   Device: Freezor Xtra Cryoablation Catheter
Sponsor:   Medtronic Atrial Fibrillation Solutions
Recruiting - verified February 2015

Management of New-Onset Postoperative Atrial Fibrillation

Conditions:   Atrial Fibrillation;   Coronary Artery Disease;   Post Operative Arrythmia
Intervention:  
Sponsors:   Emory University;   Medtronic
Recruiting - verified February 2015

Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study.

Conditions:   Atrial Fibrillation;   Peripheral Vascular Disease
Intervention:  
Sponsor:   University of Roma La Sapienza
Completed - verified February 2015

Anticoagulation in Stent Intervention

Conditions:   Atrial Fibrillation;   Stroke
Interventions:   Drug: Acetylsalicylic Acid + clopidogrel + acenocoumarol;   Drug: Acetylsalicylic Acid  + clopidogrel
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Active, not recruiting - verified February 2015

Measurement of Bispectral Index and Awareness in Patients Undergoing Electrophysiology Studies With Isoproterenol

Condition:   Intraoperative Awareness
Intervention:   Drug: Isoproterenol
Sponsor:   New York University School of Medicine
Completed - verified February 2015

Pulmonary Vein Isolation Outcomes With Fish Oils

Condition:   Atrial Fibrillation
Intervention:   Drug: Lovaza (Fish Oils)
Sponsors:   St. Luke's-Roosevelt Hospital Center;   GlaxoSmithKline
Temporarily not available - verified February 2015

Get CardioSmart

You're Invited

CardioSmart Points

Log in to Check Your Balance
and Go Shopping

Learn how to earn more CardioSmart Points